49 Total amount of colloid received (ml) 350 ± 250 300 ± 250 0.61 Blood transfusion (n) 1.15 ± 1.64 1.22 ± 1.71 0.96 Intraoperative autotransfusion (n) 0.47 ± 0.71 0.33 ± 0.62 0.82 Intraoperative body temperature (°C) 36.14 ± 0.22 36.24 ± 0.26 0.93 Intraoperative blood LXH254 glucose (mg/dl) 120.04 ± 21.38 116.63 ± 23.61 0.72 Intraoperative

MAP (mmHg) 103.66 ± 12.82 106.41 ± 12.13 0.60 Intraoperative CVP (cm H 2 O) 10.32 ± 1.23 10.14 ± 1.33 0.75 Intraoperative SpO 2 (%) 97.60 ± 0.92 96.61 ± 2.82 0.30 Arterial lactate level (mmol/l)        1 h post-surgery 0.82 ± 0.22 0.61 ± 0.34 0.82  6 h post-surgery 1.77 ± 0.32 1.87 ± 0.25 0.83  5 days post-surgery 1.32 ± 0.35 1.27 ± 0.22 0.91 Intraoperative BE (mmol/l) 0.32 ± 0.51 0.43 ± 0.38 0.53 Intraoperative PaO 2 (mmHg) 222.21 ± 10.23 215.11 ± 23.11 0.73 Pain (Verbal Rating Scale)        1 h post-surgery 1.32 ± 0.62 1.22 ± 0.81 Alisertib datasheet 0.59  6 h post-surgery 1.14 ± 0.44

1.07 ± 0.51 0.54  5 days post-surgery 0.73 ± 0.56 0.82 ± 0.64 0.46 Values are presented as mean ± SD. None of the patients experienced adverse events see more during their postoperative course such as pulmonary infections requiring antibiotic treatment, systemic inflammatory response syndrome, sepsis, acute respiratory distress syndrome, or surgical revision. Metastases after surgery were observed in only 4 out of 28 cancer patients (14.3%): one in the TIVA-TCI group and 3 in the BAL group (p = 0.28) (Table 1). No significant differences were observed in the Urease incidence of death from any cause or tumors between the TIVA-TCI and BAL groups, even though the number of patients who had died was higher in the BAL group (4 in BAL vs. 1 in TIVA-TCI, p = 0.14) (Table 1). Changes in concentrations of inflammatory cytokines TIVA-TCI patients showed a marked and significant increase in IL-6 at T1 (6–8 hours post-surgery), reaching a value of 132.6 ± 37.9 pg/ml compared

to the value of 5.3 ± 4.4 pg/ml measured before surgery (T0; p = 0.005), an increase of about 50-fold (Table 3, Figure 1). These values were reduced 5 days post-surgery (T2), but remained about 10-fold higher than baseline values (p = 0.005). Even in the BAL group, we observed a similar increase at T1 (132.4 ± 53.9 pg/ml vs. 4.2 ± 3.3 pg/ml, p = 0.005) that was followed by a reduction at T2 that remained about 10 times higher than baseline values (p = 0.005) (Table 3). No significant differences were found between TIVA-TCI and BAL groups in the levels of IL-6 just before surgery or peri-operatively. Table 3 Changes of immunologic parameters before induction of anaesthesia (T0), 6–8 hours post-surgery (T1) and 5 days post-surgery (T2) in patients who underwent TIVA-TCI and BAL anesthesia   T0 T1 T2   TIVA-TCI BAL TIVA-TCI BAL TIVA-TCI BAL IL-1β (pg/ml) 0.58 ± 0.53 0.59 ± 0.53 0.57 ± 0.48 0.62 ± 0.52 0.60 ± 0.53 0.69 ± 0.50 IFN-γ (pg/ml) 0.55 ± 0.48 0.57 ± 0.41 0.53 ± 0.42 0.58 ± 0.51 1.07 ± 0.48 (p) 0.58 ± 0.58 (p) TNF-α (pg/ml) 0.94 ± 0.64 0.